Supplemental material
Journal of Medical Economics
Volume 24, 2021 - Issue 1
Open access
3,847
Views
7
CrossRef citations to date
0
Altmetric
Oncology
Budget impact of capmatinib for adults with metastatic non-small cell lung cancer harboring a MET exon 14 skipping mutation in the United States
Beilei Caia Novartis Pharmaceuticals Corporation, East Hanover, NJ, USACorrespondence[email protected]
https://orcid.org/0000-0002-2762-3908
Zheng-Yi Zhoub Analysis Group, Inc., Boston, MA, USA
https://orcid.org/0000-0001-9014-8479
Weiguang Xueb Analysis Group, Inc., Boston, MA, USA
https://orcid.org/0000-0003-0713-2869
Nisha C. Hazrab Analysis Group, Inc., Boston, MA, USA
https://orcid.org/0000-0002-1424-6525
Mukesh Singhc Novartis Healthcare Pvt. Ltd., Hyderabad, India
, Dinesh Mishrac Novartis Healthcare Pvt. Ltd., Hyderabad, India
, Diana Brixnerd Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT, USA
https://orcid.org/0000-0001-6637-6359
Gary Oderdad Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT, USA
https://orcid.org/0000-0001-9664-0296
Joseph Biskupiakd Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT, USA
https://orcid.org/0000-0002-9436-0984
Pages 131-139
|
Received 24 Sep 2020, Accepted 14 Dec 2020, Published online: 21 Jan 2021
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.